MeSH D003922 - type 1 diabetes mellitus
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Biocon | Insulin glargine | Semglee |  | 2021-07-28 |  |  |
| Mylan | Insulin glargine | Semglee |  | 2020-06-11 |  |  |
| AstraZeneca | Pramlintide | Symlin |  | 2005-03-16 | $33 M | Q3/18-Q2/19 |
| Sanofi | Insulin lispro | Admelog |  | 2017-12-11 |  |  |
| Insulin lispro | Insulin lispro Sanofi |  | 2017-07-19 |  |  | |
| Insulin glargine | Lantus |  | 2000-04-20 |  |  | |
| Lixisenatide, Insulin glargine | Soliqua |  | 2016-11-21 |  |  | |
| Lixisenatide, Insulin glargine | Suliqua |  | 2017-01-11 |  |  | |
| Insulin glargine | Toujeo |  | 2015-02-25 |  |  | |
| Insulin glargine | Toujeo (previously Optisulin) |  | 2000-06-26 |  |  | |
| Merck Sharp & Dohme | Insulin glargine | Lusduna |  | 2017-01-03 |  |  |
| Eli Lilly | Insulin glargine | Abasaglar (previously Abasria) |  | 2014-09-09 |  |  |
| Insulin glargine | Basaglar |  | 2015-12-16 | $676.6 M | Q2/23-Q1/24 | |
| Insulin lispro | Humalog |  | 1996-06-14 | $1,741.2 M | Q2/23-Q1/24 | |
| Insulin lispro | Humalog Mix |  | 1999-12-22 |  |  | |
| Insulin lispro | Liprolog |  | 1997-05-07 |  |  | |
| Insulin lispro | Lyumjev |  | 2020-06-15 |  |  | |
| Insulin lispro | Lyumjev (previously Liumjev) |  | 2020-03-24 |  |  | |
| Insulin glargine | Rezvoglar |  | 2021-12-17 |  |  | |
| Viatris | Insulin glargine | Semglee |  | 2018-03-23 |  |  |
| Novo Nordisk | Insulin aspart, Insulin degludec | Ryzodeg |  | 2015-09-25 |  |  |
| Insulin degludec | Tresiba |  | 2015-09-25 |  |  | |
| Liraglutide, Insulin degludec | Xultophy |  | 2016-11-21 |  |  | |
| Guidehouse Germany | Sotagliflozin | Zynquista |  | 2019-04-26 |  |  |
| Provention Bio | Teplizumab | Tzield |  | 2022-11-17 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
68%71/104
Phase 2
44%62/140
Phase 3
49%38/77
Approved: 6Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use